Harnessing formulation and clinical pharmacology knowledge for efficient pediatric drug development: Overview and discussions from M-CERSI pediatric formulation workshop 2019
- PMID: 33878434
- DOI: 10.1016/j.ejpb.2021.04.010
Harnessing formulation and clinical pharmacology knowledge for efficient pediatric drug development: Overview and discussions from M-CERSI pediatric formulation workshop 2019
Abstract
A pediatric formulation workshop entitled "Pediatric Formulations: Challenges of Today and Strategies for Tomorrow" was held to advance pediatric drug product development efforts in both pre-competitive and competitive environments. The workshop had four main sessions discussing key considerations of Formulation, Analytical, Clinical and Regulatory. This paper focuses on the clinical session of the workshop. It provides an overview of the discussion on the interconnection of pediatric formulation design and development, clinical development strategy and pediatric clinical pharmacology. The success of pediatric drug product development requires collaboration of multi-disciplinary teams across the pharmaceutical industry, consortiums, foundations, academia and global regulatory agencies. Early strategic planning is essential to ensure alignment among major stakeholders of different functional teams. Such an alignment is particularly critical in the collaboration between formulators and clinical pharmacology teams.
Keywords: Age-appropriate formulation; Clinical pharmacology; Drug development; Pediatric; Pharmacokinetics.
Copyright © 2021 Elsevier B.V. All rights reserved.
Similar articles
-
Pediatric formulation development - Challenges of today and strategies for tomorrow: Summary report from M-CERSI workshop 2019.Eur J Pharm Biopharm. 2021 Jul;164:54-65. doi: 10.1016/j.ejpb.2021.04.011. Epub 2021 Apr 18. Eur J Pharm Biopharm. 2021. PMID: 33878432
-
Accelerating Process Development and Product Formulation.Pharm Res. 2024 May;41(5):833-837. doi: 10.1007/s11095-024-03708-z. Epub 2024 May 2. Pharm Res. 2024. PMID: 38698195
-
Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatrics Formulation Initiative: proceedings from the Second Workshop on Pediatric Formulations.Clin Ther. 2012 Nov;34(11):S1-10. doi: 10.1016/j.clinthera.2012.09.013. Clin Ther. 2012. PMID: 23149008
-
Dissolution and Translational Modeling Strategies Enabling Patient-Centric Drug Product Development: the M-CERSI Workshop Summary Report.AAPS J. 2018 Apr 9;20(3):60. doi: 10.1208/s12248-018-0213-x. AAPS J. 2018. PMID: 29633092
-
Industry Perspective on Using MIDD for Pediatric Studies Requiring Integration of Ontogeny.J Clin Pharmacol. 2019 Sep;59 Suppl 1:S112-S119. doi: 10.1002/jcph.1495. J Clin Pharmacol. 2019. PMID: 31502694 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical